RxDoctor Payments Data

Mark Timmerman, MD

Family Medicine · Manchester, NHNPI 1972525574

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 264 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 30.3% of the total. Reporting peaked in 2019 at $1,655 and has fallen 95.3% since, to $77 in 2024. Among family medicine clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,453in general payments, 2019–2025

Across 264 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$624
  • Merck$411
  • Novo Nordisk$400
  • Lilly USA, LLC$362
  • Boehringer Ingelheim$324
  • plus $983 from 13 others

What the payments were for

  • Food & beverage$4,453100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,453 in reported general payments places this provider in the 95th percentile of 397 family medicine providers in New Hampshire.

See all family medicine providers in New Hampshire

Medicare billing

Part B allowed, 2024
$21,978
Medicare patients
76
Services billed
281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin13$9,181
Nebivolol Hcl24$1,242
Levothyroxine Sodium34$319
Rosuvastatin Calcium39$273
Tamsulosin Hcl16$144
Omeprazole16$107
Escitalopram Oxalate11$83
Ibuprofen11$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$324$9,18113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 397 family medicine providers in New Hampshire.

Other family medicine in Manchester

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →